ClinConnect ClinConnect Logo
Search / Trial NCT04123808

IpsiHand System for Rehabilitation of the Arm and Hand After Stroke

Launched by COLUMBIA UNIVERSITY · Oct 10, 2019

Trial Information

Current as of July 21, 2025

Withdrawn

Keywords

Stroke Hemiparesis Rehabilitation Upper Extremity Neurological Rehabilitation Neuronal Plasticity Brain Computer Interfaces Robotics

ClinConnect Summary

This trial aims to assess the effectiveness of the NeuroLutions Upper Extremity Rehabilitation System, known as IpsiHand, on functional motor recovery and neuroplasticity for chronic stroke survivors with hemiparesis (N=27). The IpsiHand system involves a Brain-Computer Interface (BCI) as a control for a robotic hand orthosis. Participants will complete 16-32 weeks of home therapy with the IpsiHand system.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Diagnosis of stroke(s), with most recent stroke at least 6 months prior to study start (can be ischemic or hemorrhagic)
  • PROM: Full extension of digits 2 and 3 at MPs, PIPs, and DIPs
  • English speaking
  • Intact cognition to provide informed consent
  • Intact language skills to comprehend and follow directions
  • Experiencing difficulty performing ADLs with affected upper limb
  • Upper extremity Botox allowable, but not required
  • Botox users must continue regimen at regular intervals for duration of study
  • Botox users will provide clinic note for each injection (date, dose, and muscle location)
  • Botox + Study Schedule
  • At study initiation, Botox injection will occur between 3-7 days prior to baseline measurement and initiation of device use
  • Repeat Botox injections must be completed at least 3 days prior to any administration of the outcome measures
  • Exclusion Criteria:
  • Concurrent participation in another study
  • Co-morbid orthopedic condition/pain limiting functional use of the impaired upper limb
  • History of neurological disorder other than stroke
  • Botox user unable to comply with above noted requirements
  • Ongoing physical or occupational therapy addressing the upper limb
  • Ongoing electric stimulation or other rehabilitative devices (e.g. robotics, virtual reality) to upper limb
  • Cognitive impairment: Short Blessed Test Score 9
  • Significant spasticity: Modified Ashworth Scale score 3 at the elbow
  • Significant hemispatial neglect: Mesulam Cancellation Test 3 unilaterally
  • Insufficient Strength: Motricity Index score for shoulder abduction 18
  • Significantly impaired sensation of impaired upper limb: National Institutes of Health Stroke Scale - Item 8 (Sensory) score of 2
  • History of cranioplasty
  • History of seizure disorder
  • No changes to usual exercises, splint use, or oral baclofen/anti-spasticity medication use during trial

About Columbia University

Columbia University, a prestigious Ivy League institution located in New York City, is a leading sponsor of clinical trials dedicated to advancing medical research and improving patient care. With a robust network of research facilities and a commitment to innovation, Columbia University collaborates with a diverse range of healthcare professionals and researchers to explore groundbreaking therapies and treatment methodologies. The university's clinical trials encompass various fields, including oncology, neurology, and public health, aiming to translate scientific discoveries into effective clinical applications. Columbia University is dedicated to maintaining the highest ethical standards and regulatory compliance, ensuring the safety and well-being of trial participants while contributing to the global body of medical knowledge.

Locations

Patients applied

0 patients applied

Trial Officials

Joel Stein, MD

Principal Investigator

Columbia University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials